compound semaglutide news Troubling Findings in Study of GLP-1 Compounders compounding semaglutide news FDA alerts

Here are some of the findings of the JAMA study: Taking a semaglutide to treat type 2 diabetes is associated with a four times higher risk of developing NAION compared to other medications

Seek out online forums, support groups, or wellness communities where you can connect with others who share similar health goals

These drugs typically curb appetite, help you feel fuller faster, reduce food cravings, slow digestion, and control blood sugar

Tirzepatide generated roughly $36.5 billion of Lillys $65.2 billion in 2025 revenue, and management guided for $80 billion to $83 billion in 2026

Nevertheless, heterogeneity in formulations, dosing (typically 24 g/day), and treatment duration across studies tempers definitive conclusions

Liu HC, et al